Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Forte Biosciences, Inc.NASDAQ: FBRX
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$58.22M, compared with -$45.86M a year earlier.
Context
- Net debt amounted to 86.6% of total assets at the end of Q1 FY2026, down 10.0 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -27.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (76.96M) USD
- Year-over-year change
- -246.0%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (76.96M) | -246.0% |
| FY2024 | 2024-12-31 | (22.24M) | -86.0% |
| FY2023 | 2023-12-31 | (11.96M) | +70.9% |
| FY2022 | 2022-12-31 | (41.1M) | +2.2% |
| FY2021 | 2021-12-31 | (42.04M) | — |
Net Debt vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -27.0% is the 7th highest of 10, against a peer median of -0.9%.
- Net debt amounts to 86.6% of total assets for FBRX, versus a peer median of 16.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $47.64M USD | +81.1% | -6.8% | 12.8% | |
| Mar 2026 | $37.22M USD | -3.1% | -13.4% | 13.1% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | -$608K USD | +95.2% | — | 2.7% |
ACTUActuate Therapeutics Inc | Mar 2026 | -$7.73M USD | -98.7% | — | 86.7% |
| Mar 2026 | -$7.9M USD | +65.3% | — | 16.1% | |
| Mar 2026 | -$24.84M USD | -54.8% | — | 17.2% | |
| Mar 2026 | -$25.59M USD | -0.9% | — | 16.4% | |
| Mar 2026 | -$42.41M USD | -1479.3% | — | 17.7% | |
| Mar 2026 | -$58.22M USD | -27.0% | — | 86.6% | |
| Mar 2026 | -CHF 75.2M CHF | +5.1% | — | 86.0% | |
| Peer median (excluding FBRX) | — | -0.9% | -10.1% | 16.4% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.